Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Select Inclusion Criteria:~1. Diagnosis of idiopathic pulmonary fibrosis (IPF), consistent with the ATS 2011 Guidelines, of 6-48 months' duration~2. Age 40 to 80 at randomization~3. Percent Forced Vital Capacity (%FVC) ≥50% and ≤90% at screening~4. Percent Carbon Monoxide Diffusing Capacity (%DLCO) ≥30% and ≤90% at screening~Select Exclusion Criteria:~1. Forced expiratory volume in one second (FEV1)/FVC ratio \<0.8 after administration of bronchodilator at Screening~2. Expected to receive a lung transplant within 1 year from randomization or, for patients at sites in the United States, on a lung transplant waiting list at randomization~3. Known explanation for interstitial lung disease~4. History of asthma or chronic obstructive pulmonary disease~5. Active infection~6. Ongoing IPF treatments including investigational therapy, immunosuppressants, and cytokine modulating agents~7. History of unstable or deteriorating cardiac or pulmonary disease (other than IPF) within the previous 6 months

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Active Arm (Type: ACTIVE_COMPARATOR): None
- Placebo Arm (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).